2Shepherd J, Blarw GJ, Murphy MB, et al. Pravasiatin in elderly individuals at risk of vascular disease (PROSPER ) : a rand,)mised controlled trial[J]. Lancet ,2002,60 ( 9346 ) : 1623 - 1630.
3Austin PC, Mamdani MM. Impact of the pravaslatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial in - faretion 22/Reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in ontario,Canada [J]. Circulation, 2005,12 ( 9 ) : 1296 - 1300.
4Nissen SE, Juzcu EM, Schoenhagen P, el al. Effect of intensive compared with moderate lipid - lowering therapy on progression of coronary atherosclerosis [J]. JAMA, 2004,291 : 1071 - 1080.
5Von Birgelen C.Hartmann M,Mintz GS,et al. Relation between progression and regression of atherosclerotic left main coronary artel7 disease and serun cholesterol levels as assessed with serial long - term ( 12 months) follow up intravascular ultrasound[J]. Circulation ,2003, 108:2757 - 2762.
6Williams K J, Feig JE, Fisher EA. Rapid regression of alheroselerosis: insights from the clinical and experimental literature [J]. Nat elin praet Cardiovasc Med ,2008,5 ( 2 ) :91 - 102.
9Young -xu Y ,Jabbour S, Gohlberg R, et al. Usefulness of stain drugs in protecting against atrial fibrillation in patients with Coronary artery disease[J]. Am J Cardiol, 2003,92 ( 12 ) : 1379 - 1383.
10Marin F, Pascual DA, Roldan V,et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting [J]. Am J Cardiol,2006,97 ( 1 ) :56 - 60.
6Ridker P, Rifai N, Preffer M, et al. Long-term effects of pravastation on plasma concentration of C-reactive protein [J].Circulation, 1999,100(6) : 230.
7Engstron G, Lind P, Heelblad B, et al, Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men[J]. Circulation, 2002,105(22) :3632.
8Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis[J], JACC,2000,35(6):1535.
9Morrow DA, Ridker PM. C-reactive protein, inflammation,and coronay risk[J]. Med Clin North Am, 2000,84(1) :149.
10Kosuge M, Kimura K, Ishikawa T, et al, Relation between C-reactive protein levels on admission and acute myocardial infarction onset[J], Am J Cardiol, 2000,86(3) :83.
5Michel ML,Deng Q,Mancini-Bourgine M.Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B:perspectives and challenges[J].JHepatol,2011,54(6):1286-1296.
